Evaluating ZNF217 mRNA Expression Levels as a Predictor of Response to Endocrine Therapy in ER+ Breast Cancer
Julie A. Vendrell(Inserm), Pascale A. Cohen(Lyon 1 Université), Marta Jarlier(Institut de Recherche en Cancérologie de Montpellier), Balázs Győrffy(Semmelweis University), Laurent Gamba(Université de Montpellier), Jérôme Solassol(Inserm), Thierry Maudelondé(Université de Montpellier), Caterina F. Donini(Sapienza University of Rome), Paul Vilquin(Université Claude Bernard Lyon 1), Philippe Rouanet(Université de Montpellier)
Cited by 17
Related Papers
Online Survival Analysis Software to Assess the Prognostic Value of Biomarkers Using Transcriptomic Data in Non-Small-Cell Lung Cancer
|PLoS ONE|2013|1.9k
Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER)
|The Lancet Oncology|2014|410
Cracking the Estrogen Receptor's Posttranslational Code in Breast Tumors
|Endocrine Reviews|2011|302
Identification of novel genes that co-cluster with estrogen receptor alpha in breast tumor biopsy specimens, using a large-scale real-time reverse transcription-PCR approach
|Endocrine Related Cancer|2006|239
Genome-wide reprogramming of the chromatin landscape underlies endocrine therapy resistance in breast cancer
|Proceedings of the National Academy of Sciences|2013|185